Cas:17145-91-4 Triethyl 2-phosphonobutyrate manufacturer & supplier

We serve Chemical Name:Triethyl 2-phosphonobutyrate CAS:17145-91-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Triethyl 2-phosphonobutyrate

Chemical Name:Triethyl 2-phosphonobutyrate
CAS.NO:17145-91-4
Synonyms:triethyl 2-phosphonobutyrate;MFCD00041347
Molecular Formula:C10H21O5P
Molecular Weight:252.24500
HS Code:2931900090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:152-154ºC (14 torr)
Density:1.064
Index of Refraction:n20/D 1.432(lit.)
PSA:71.64000
Exact Mass:252.11300
LogP:2.59420

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like triethyl 2-phosphonobutyrate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00041347 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00041347 Use and application,triethyl 2-phosphonobutyrate technical grade,usp/ep/jp grade.


Related News: The national airlines of Egypt, Qatar and Saudi Arabia have halted flights to and from China. Triethyl 2-phosphonobutyrate manufacturer AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment. Triethyl 2-phosphonobutyrate supplier The FDA said its decision allows for the J&J doses to be used in the United States or exported. T Triethyl 2-phosphonobutyrate vendor First of all, as an API manufacturer we think of how to make a chemical compound which becomes an API in the laboratory. Triethyl 2-phosphonobutyrate factory AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment.